Sudeep Pharma Q1 FY27: Revenue up 27%, PAT jumps 30% on consol basis

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

SUDEEPPHRM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.8%Reaction day

₹873.00

prior close

₹818.40

announcement price

After-mkt

timing

Nifty Microcap 250market+1.3%+8.6% vs market

Specialty Chemicals peers, median of 94sector+0.0%+9.8% vs sector

On the reaction day the stock moved 8.6 pts more than Nifty Microcap 250 and 9.8 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.9

15m

+0.8

30m

+4.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.8+1.3+8.6+0.0+9.8

Next day

+11.7+1.6+10.0+0.1+11.6

+10.0+1.7+8.3+0.0+9.9

+20.7+1.6+19.0+1.0+19.7

+27.7+1.5+26.3+0.8+26.9

+26.9+1.8+25.1+0.3+26.7

+26.0+2.1+23.9+0.6+25.4

15d

+29.1+3.2+25.9+2.2+26.9

+51.6+3.7+47.9+2.6+49.1

+35.1+1.1+33.9-0.8+35.8

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 (ended 30 June 2026) results. Consolidated revenue jumped 26.7% YoY to Rs. 15,827.05 lakhs, PAT up 29.8% to Rs. 4,058.69 lakhs, EPS Rs. 3.59. Standalone revenue rose 31.8% to Rs. 10,568.33 lakhs, PAT up 34.2% to Rs. 3,382.85 lakhs. Both pharma and speciality ingredients segments grew. Auditor gave clean limited review.

Likely market impact

Strong Q1 with healthy double-digit revenue and profit growth across both consolidated and standalone results. Recent NSS Ireland acquisition added to scale.